- •Peripheral administration of epirubicin can cause phlebitis.
- •Limited evidence exists for epirubicin administration methods to reduce phlebitis.
- •Infusion pump administration of epirubicin increased patient-reported phlebitis.
- •No significant difference in phlebitis severity on clinical assessment.
- •A transient increase in phlebitis severity compared to manual injection method.
To establish the incidence and severity of chemotherapy-induced phlebitis (CIP) following administration of epirubicin chemotherapy using a volumetric infusion pump (Hospira Plum 360), compared to a previous study of manual injection of epirubicin. Secondly to gain insight into staff perceptions of ease of use and safety of infusion pump administration.
An observational study of women with breast cancer (n = 47) receiving epirubicin via volumetric infusion pump. Phlebitis was reported through a participant self-assessment questionnaire and graded by clinical assessment three weeks after each chemotherapy cycle. Staff perceptions were explored using questionnaires.
Infusion pump administration delivered a significantly higher concentration of epirubicin (p < 0.001), a significantly higher rate of grade 3 and 4 participant reported CIP between cycles (p = 0.003) but demonstrated no significant difference in grade 3 and 4 CIP when assessed clinically three weeks after treatment (p = 0.157).
Peripheral epirubicin administration will result in severe CIP being experienced by a proportion of patients irrespective of whether infusion pump or manual injection method is used. Those at high risk of severe CIP should be informed of the risk and offered a central line. For those with a lower risk of severe phlebitis use of the infusion pump appears to be a safe option.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Oncology Nursing
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Upper limb venous thromboembolism in early breast cancer patients on chemotherapy: a single centre experience.Clin. Oncol. 2017; 29: e97https://doi.org/10.1016/j.clon.2017.01.013
- Improving outcomes of short peripheral vascular access in oncology and chemotherapy administration.J. Vasc. Access. 2017; 18: 89-96https://doi.org/10.5301/jva.5000668
- Facts and Statistics 2021.2021 (Available at:)https://breastcancernow.org/about-us/media/facts-statisticsDate accessed: February 7, 2023
- Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.Future Oncol. 2019; 15: 297-303https://doi.org/10.2217/fon-2018-0662
- Breast cancer statistics.(Available at:)https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancerDate: 2018Date accessed: February 7, 2023
- Cancer therapy venous access device decision guide.UK Oncology Nursing Society (UKONS). 2014; (Available at:)https://www.ukons.org/site/assets/files/1138/cvaddecisionguide.pdfDate accessed: February 13, 2023
- Differential impact of fosaprepitant on infusion site adverse events between cisplatin-and anthracycline-based chemotherapy regimens.Anticancer Res. 2015; 35: 379-383
- Development of the UK vessel Health and preservation (VHP) framework: a multi-organisational collaborative.Journal of Infection Prevention. 2016; 17: 65-72https://doi.org/10.1177/175177415624752
- UK vessel Health and preservation (VHP) framework: a commentary on the updated VHP 2020.Journal of Infection Prevention. 2021; 22: 147-155https://doi.org/10.1177/175177420976806
- Audit of Breast Cancer Chemotherapy Related Phlebitis.Cardiff. Velindre NHS Trust, 2014 (details available on request from lead author)
- The development and testing of a chemotherapy-induced phlebitis severity (CIPS) scale for patients receiving anthracycline chemotherapy for breast cancer.J. Clin. Med. 2020; 9: 701https://doi.org/10.3390/jcm9030701
- Proactive placement of peripherally inserted central catheters.Br. J. Nurs. 2015; 24: S16-S17https://doi.org/10.12968/bjon.2015.24.Sup14.s16
- Methods of preventing vinorelbine-induced phlebitis: an experimental study in rabbits.Int. J. Med. Sci. 2008; 5: 218-223https://doi.org/10.7150/ijms.5.218
- Complications of delivering IV chemotherapy.(Available at:)https://hospitalpharmacyeurope.com/news/editors-pick/complications-of-delivering-iv-chemotherapy/Date: 2015Date accessed: February 7, 2023
- Chemotherapy for breast cancer.(Available at:)https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/chemotherapy-for-breast-cancerDate: 2018Date accessed: February 7, 2023
- Management of chemotherapy-related arm symptoms in patients with breast cancer.Cancer Nurs. Pract. 2015; 14: 22-28https://doi.org/10.7748/cnp.14.2.22.e1163
- Vessel Health and Preservation: the Right Approach for Vascular Access.Springer Nature, Germany2019https://doi.org/10.1007/978-3-030-03149-7
- Guideline NG101 Early and locally advanced breast cancer: diagnosis and management.(Available at:)https://www.nice.org.uk/guidance/ng101Date: 2018Date accessed: February 7, 2023
- Think superficial thrombophlebitis, because time might be of the essence.Nurs. Stand. 2021; 36: 70-72
- Patient safety in the context of phlebitis reported in a university hospital.Revista de Epidemiologia e Controle de Infecção. 2019; 9: 109-115https://doi.org/10.17058/reci.v9i2.12099
- Epirubicin chemotherapy in women with breast cancer: alternating arms for intravenous administration to reduce chemical phlebitis.Eur. J. Cancer Care. 2019; 28e13114https://doi.org/10.1111/ecc.13114
- Identifying risk factors for anthracycline chemotherapy-induced phlebitis in women with breast cancer: an observational study.Clin. Oncol. 2021; 33: 230-240https://doi.org/10.1016/j.clon.2020.11.025
- Risk factors for vascular trauma during antineoplastic chemotherapy: contributions of the use of relative risk.Acta Paul. Enferm. 2012; 25: 448-452https://doi.org/10.1590/S0103-2100201200300020
- Risk factors for peripheral intravenous catheter-related phlebitis in adult patients.Rev. Esc. Enferm. USP. 2022; 56e20210398https://doi.org/10.1590/1980-220X-REEUSP-2021-0398en
- Morbidity of chemotherapy administration and satisfaction in breast cancer patients: a comparative study of totally implantable venous access device (TIVAD) versus peripheral venous access usage.World J. Surg. 2014; 38: 1084-1092https://doi.org/10.1007/s00268-01302378-x
- Pre-Procedural Considerations. The Royal Marsden Manual of Clinical and Cancer Nursing Procedures.2020 (Available at:)rmmonline.co.ukDate accessed: September 24, 2022
- Offering breast cancer patients a choice of device for administration of chemotherapy: a service improvement project.Cancer Nurs. Pract. 2020; 21https://doi.org/10.7748/cnp.2020.e1692
- An observational study of the effect of dilution and delivery speed on the development of phlebitis after epirubicin chemotherapy.Cancer Nurs. Pract. 2019; 21https://doi.org/10.7748/cnp.2019.e1585
- Decrease in the vinorelbine-induced venous irritation by pharmaceutical intervention.Support. Care Cancer. 2012; 20: 1549-1553https://doi.org/10.1007/s00520-011-1244-3
- Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.Molecular and Clinical Oncology. 2019; 11: 43-49https://doi.org/10.3892/mco.2019.1849
Accepted: March 10, 2023
Received in revised form: February 25, 2023
Received: November 14, 2022
Publication stageIn Press Accepted Manuscript
© 2023 Published by Elsevier Ltd.